This Solicitation opportunity from Department Of Defense was posted on May 7, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Closed

HT9402-26-Q-9302Federal

Submission Closed05/28/2026, 05:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

METOPROLOL TARTRATEThe contract pertains to the procurement of Metoprolol Tartrate, identified by the National Stock Number 6505-01-615-1537, with a requested quantity of one unit under purchase request number 7017142424. The solicitation, numbered SPE2DP-26-T-3815, was posted by the Defense Logistics Agency, a branch of the Department of Defense, on June 16, 2026. The deadline for responses to this solicitation is June 22, 2026, indicating a brief window for bid submissions. This contract is categorized as a solicitation from a federal agency, with no specified type of set-aside or NAICS code provided. The place of performance and office location details are unspecified beyond being within the United States. The solicitation is accessible through the Defense Logistics Agency’s bidding system, and it appears focused on securing this specific pharmaceutical item for defense-related use.

Defense Logistics Agency

POSTED

DEADLINE

Wound Infection Prevention & Sepsis Countermeasure DevelopmentThe contract involves the development of a drug/device combination product aimed at preventing or treating wound infections and sepsis specifically in battlefield or austere environments. The project is targeted to advance this product to Phase I clinical trials under the FDA 505(b)(2) regulatory pathway, which facilitates the approval process by leveraging existing data. This effort is intended to address critical medical needs encountered by military personnel in challenging settings, ensuring rapid and effective countermeasures against potentially life-threatening infections. Issued by the Army Medical Resources Acquisition Activity under the Department of Defense, the contract is a subcontract with a focus on the pharmaceutical manufacturing sector (NAICS code 325412). The work will be performed in Frederick, capturing the strategic importance of this location for medical research and development. The solicitation was posted on June 16, 2026, with a response deadline of July 17, 2026, highlighting a clear and concise timeline for interested parties. This project underscores a high-priority initiative to enhance battlefield medical capabilities through innovative therapeutic solutions.

Army Medical Resources Acq Activity

POSTED

DEADLINE

6505--Dutasteride CapsulesThe Department of Veterans Affairs National Acquisition Center plans to issue a Request for Proposal (RFP 36E79726R0029) for the procurement of Dutasteride Capsules to serve multiple federal agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted contract aims to secure a reliable supply source for Dutasteride 0.5MG capsules in both 30-count and 90-count bottles, with annual estimated usage of approximately 3,912 and 25,502 bottles respectively. The contract will be awarded to a single responsible offeror who can provide an uninterrupted supply and will have a one-year base period followed by four one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must supply the drug under the exact name on the label, with a unique National Drug Code (NDC) exclusive to the offeror. The contractor’s label must be the sole label on the product, with VA labels designed to adhere securely on top without obscuring important information such as barcodes, expiration dates, and lot numbers. Packaging requirements include safety caps that meet specific design criteria with a minimum bottle volume of 120cc and cylindrical shape to accommodate appropriate labeling sizes. The solicitation will be released in a commercial item format in accordance with FAR Part 12 around June 22, 2026, with proposals due by July 7, 2026. Interested parties should monitor SAM.gov for updates and submit offers electronically; efforts to obtain paper copies will not be accommodated. The contract specialist and primary point of contact for this procurement is Richard Mahario.

Nac Pharmaceuticals (36E797)

POSTED

DEADLINE

LEVOFLOXACIN TABLETThe contract pertains to the procurement of Levofloxacin tablets, identified by NSN/Part Number 6505-01-444-6632, with a purchase quantity of one unit under request number 7017178498. The solicitation, designated SPE2DP-26-T-3807, was issued by the Defense Logistics Agency on behalf of the Department of Defense with a posting date of June 15, 2026, and a response deadline set for June 22, 2026. This solicitation is categorized as a federal opportunity without specific set-aside conditions or NAICS code information provided. The contract will be performed within the United States, although exact location details are unspecified. The Defense Logistics Agency is managing the acquisition, and the solicitation details are accessible via a designated DIBBS URL for interested parties.

Defense Logistics Agency

POSTED

DEADLINE

Sole Source Total Parenteral Nutrition (TPN) solutions, including TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid same-day delivery, seven days a weekThis contract involves the sole source procurement of Total Parenteral Nutrition (TPN) solutions, specifically including products such as TrophAmine, Plenamine, Nutrilipid, and SMOF Lipid. The key requirement is for same-day delivery, seven days a week, ensuring continuous availability of these critical nutritional solutions. The solicitation number is HT941026N0069, with the notice posted on June 15, 2026, and a response deadline set for June 30, 2026. The contract falls under the NAICS code 325412, associated with pharmaceutical preparation manufacturing, and is issued by the Defense Health Agency located at Camp Pendleton, California. The place of performance is identified within Washington state, ZIP code 98431, indicating where the deliveries or contract services will be conducted. There is no set-aside designation for this procurement, reflecting an open competitive strategy or a direct sole-source justification. Primary and secondary points of contact are provided for further inquiries, with the primary contact being CHA-ON Gordon. The contract aims to support the Department of Defense’s ongoing medical and nutritional needs for personnel, emphasizing timely and reliable supply chain delivery for essential TPN products.

Defense Health Agency Hcd West

POSTED

2 days ago

DEADLINE

in 14 days

AI Contract Overview

The Department of War, under the mandate of federal law and regulations, is tasked with establishing a comprehensive and integrated pharmacy benefits program for the Military Health System, which involves the procurement of pharmaceutical agents. This program is guided by the Pharmacy and Therapeutics Committee, which evaluates the clinical and cost effectiveness of drugs within therapeutic classes to decide their inclusion and classification in the Uniform Formulary. Pharmaceutical agents will be categorized for cost sharing purposes as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. As part of this process, a Request for Quotation (RFQ) has been issued to solicit bids from industry suppliers for agents within drug classes selected for the Uniform Formulary. The Defense Health Agency will subsequently award Blanket Purchase Agreements and Additional Discount Program Agreements based on the Committee’s recommendations. The upcoming Pharmacy and Therapeutics Committee meeting in May 2026 will review newly approved drugs including Lifyorli (an oncological glucocorticoid receptor antagonist), Quiofic (a water-soluble vitamin), Widaplik (an antihypertensive agent), and Saphnelo (an immunosuppressive agent). Interested parties must participate in a pre-quotation teleconference scheduled for May 13, 2026, and submit responses to clinical questions by the specified deadlines detailed in the RFQ document HT9402-26-Q-9302. The solicitation is managed by the Defense Health Agency at JBSA Fort Sam Houston, Texas, with response submissions due by May 28, 2026. Points of contact for this solicitation are provided for assistance and further inquiries.

General Info

Department of War seeks bids for Military Health System pharmacy benefits; awards follow committee evaluation.

Agency

Department Of Defense → Defense Health Agency (dha)

NAICS

325412 - Pharmaceutical Preparation Manufacturing View NAICS

Place of Performance

San Antonio, TX, 78230, USA

Set-Aside

NONE

Documents

(9)

UF BPA NDC Price List for Antihypertensive Agents August 2026

XLSX•price-list

Price Appendix FAQ for RFQ Submission

PDF•faq

UF BPA NDC Price List for August 2026 DoW P&T Meeting - Vitamins Water Soluble

XLSX•price-list

DoD Formulary Placement of FDA Newly Approved Innovator Drugs

PDF•special-notice

UF BPA NDC Price List for Oncological Agents - Glucocorticoid Receptor Antagonist

XLSX•price-list

RFQ HT9402-26-Q-9302 Uniform Formulary Pharmacy Pricing

PDF•rfq

RFQ HT9402-26-Q-9302 Uniform Formulary Pharmacy Pricing

PDF•rfq

UF BPA NDC Price List for Immunosuppressives August 2026 DoW P&T Meeting

XLSX•price-list

Amendment 1 to RFQ HT9402-26-Q-9302

PDF•amendment

AI Contract Breakdown

Uniform Contract Format

Timeline

1 update

PhaseClosed

PostedMay 7

Solicitation

Amendment 0May 7

Contract was updated

Response DeadlineMay 28

Deadline has passed

Submission Closed

05/28/2026, 05:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → Defense Health Agency (dha)

Contacts2 people available

OfficeJBSA FT SAM HOUSTON, TX, 78234, USA

Organization / Agency

Department Of Defense → Defense Health Agency (dha)

Office AddressJBSA FT SAM HOUSTON, TX, 78234, USA

Contacts

Tracy Banks

contact@example.gov

Kirk Heyen

contact@example.gov

Full Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed:

a. Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist

b. Quiofic - VITAMINS - WATER SOLUBLE

c. Widaplik - ANTIHYPERTENSIVE AGENTS – N/A

d. Saphnelo – IMMUNOSUPPRESSIVES – N/A

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9302.

Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.